Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
2 hedge funds and large institutions have $460K invested in Sage Therapeutics in 2025 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0.09% less ownership
Funds ownership: 0.09% → 0% (-0.09%)
7% less capital invested
Capital invested by funds: $494K → $460K (-$34K)
60% less funds holding
Funds holding: 5 → 2 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$35.1K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
-$3.86K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| $460K | – | – | – |
|
|
HNB
2
Huntington National Bank
Columbus,
Ohio
| $9 | – | – | – |
|
|
3
Osaic Holdings
Scottsdale,
Arizona
| – | -$35.1K | -4,045 | Closed |
|
|
IA
4
IFP Advisors
Tampa,
Florida
| – | -$3.86K | -445 | Closed |
|
SAGE Hedge Fund Activity: Q4 2025 in Review
2 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q4 2025, worth a combined $460K — down 6.9% from $494K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SAGE and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Osaic Holdings, exiting entirely with an estimated $35.1K sold.
- 2 institutional investors held Sage Therapeutics (SAGE) as of Q4 2025, down from 5 in Q3 2025.
- Funds reported $460K of Sage Therapeutics stock for Q4 2025, down 6.9% quarter-over-quarter.
- 0 funds opened new Sage Therapeutics positions in Q4 2025 and 3 closed out, a net change of -3 holders.
- The largest Sage Therapeutics seller in Q4 2025 was Osaic Holdings, an estimated $35.1K sold.
Based on aggregated 13F filings for Q4 2025.